TrialAnnals of hematology2026

Short-term blinatumomab for B-cell acute lymphoblastic leukemia pediatric patients results in measurable residual disease clearance.

Changwen Xue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.